A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
A Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Sponsor: Antengene (Hangzhou) Biologics Co., Ltd.
Terminated
The sponsor has decided to adjust the development strategy of the investigational drug in this study.
Other Advanced Solid Tumor trials with similar outcome
A PHASE1 clinical study on Advanced Solid Tumor and Mature B-cell Non-Hodgkin Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Antengene (Hangzhou) Biologics Co., Ltd. and has accumulated 9 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Oct 2023 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
First recorded
Jan 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Antengene (Hangzhou) Biologics Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .